With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?
Answer from: Medical Oncologist at Community Practice
Most importantly, carboplatin/etoposide/atezolizumab is now the standard of care first line therapy in patients with ES-SCLC. In the patients who receive atezolizumab, I would typically not treat with checkpoint inhibitor monotherapy in the third line, I would prefer a clinical trial. If a patient w...
Sign in or Register to read more